Proceedings
| # | Title of the Talks | Page No | Download |
|---|---|---|---|
| 1 | Overcoming Challenges in the Development of mRNA Therapeutics Dr. Andreas M Papas |
1 |  |
| 2 | Antiemetics sparring modality based on Adequacy of Anaesthesia guidance combined with different pre-analgesia techniques for head and neck surgeries summary from four most recent studies Dr. Michal J Stasiowski |
2 | |
| 3 | Why CEOs need advanced education and training for optimizing decisions in the development of innovative medicinal products Justification and recommendation Dr. Peter Jurgen Kramer |
4 | |
| 4 | Knowledge, Attitudes, and Perceptions of Chronic Patients in Saudi Arabia Regarding the Use of Artificial Intelligence to Improve Medication Adherence Dr. Safaa Mohammed M Alsanosi |
5 | |
| 5 | Integrating advanced molecular dynamics simulations and AI to investigate and modulate ABC transporters involved in cancer multidrug resistance Dr. Ahmad Elbahnsi |
7 | |
| 6 | Research progress in analytical methods and devices for some groups of pharmaceutical, food and environmental analytes Prof. Jan Labuda |
9 | |
| 7 | The Skin as a Reflection of Our Lifestyle Dr. Juergen Lademann |
10 | |
| 8 | KDM6AB Mediated Epigenetic Regulation of Constitutive Androgen Receptor Expression in Prostate Cancer Dr. Gokce Yildirim Buharalioglu |
11 | |
| 9 | Neurosyphilis A Rare Cause of Encephalitis in a Young Male Dr. William Cunningham |
12 | |
| 10 | The Dual-active G9a inhibitor and Histamine H3 Receptor Antagonist A-366 Ameliorates Autism-Like Phenotypes, Neuroinflammation and Oxidative Stress in BTBR Ttfj Mice Prof. Bassem Shaban Sadek |
13 | |
| 11 | A self-adjuvanted protein nanoparticle that stimulates Ultra-High affinity antibodies Dr. Ming Chung Kan |
15 | |
| 12 | Twinning and Individuation An Appraisal of the Current Model and Ethical Implications Dr. Francis J. O’Keeffe |
16 | |
| 13 | Implementation of a population health-based goal directed medical therapy program- Cardiac Kidney Metabolic Compass Dr. Mallika L Mendu |
17 | |
| 14 | Repositioning of FDA-Approved Pharmaceuticals against EpsteinBarr Virus Nuclear Antigen 1 (EBNA1) A Molecular Docking and Molecular Dynamics Study Dr. Fatemeh Karimzadeh |
18 | |
